Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910585 | 1.00 | RIPK1 (0.68) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL31656042 | 0.90 | RIPK1 (0.64) | RIPK1 | |
| SCHEMBL19207881 | 0.89 | RIPK1 (0.65) | RIPK1 | |
| SCHEMBL19207883 | 0.89 | RIPK1 (0.65) | RIPK1 | |
| SCHEMBL31655905 | 0.85 | RIPK1 (0.60) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL3915686 | 0.84 | MME (0.57) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL3913698 | 0.83 | RIPK1 (0.64) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL3911195 | 0.83 | SCN9A (0.51) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL19255334 | 0.83 | RIPK1 (0.57) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL12345835 | 0.83 | RIPK1 (0.58) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018007973-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZOXAZEPINES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-11 | — | — | WO | claimed |
| WO-2018007973-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZOXAZEPINES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-11 | — | — | WO | disclosed |
| EP-2956452-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-23 | — | — | EP | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
| EP-2029555-A2 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135295-A2 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | CYP4B1, AADAC, ALKBH3 | RIPK1 4874/4885NR1I2 1474/4885CYP2C9 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.